PPARG and proliferative diabetic retinopathy: On the other hand, the PPAR-γ agonist, such as rosiglitazone, was verified to significantly delay the progression of proliferative diabetic retinopathy, as the rates of proliferative diabetic retinopathy occurred in 19.2% in patients using rosiglitazone and 47.4% in patients using placebo.